<DOC>
	<DOCNO>NCT03102606</DOCNO>
	<brief_summary>To assess Duration Severe Neutropenia ( DSN ) treatment Cycle 1 patient advanced metastatic breast cancer , fail &gt; /= 1 &lt; 5 prior line chemotherapy ; advanced metastatic non-small cell lung cancer ( NSCLC ) fail platinum base therapy ; hormone refractory ( androgen independent ) metastatic prostate cancer treat docetaxel ( 75 mg/m2 ) + plinabulin ( RP3D ) versus docetaxel ( 75 mg/m2 ) + pegfilgrastim ( 6 mg ) . Neutrophils count assess baseline ; Pre dose Cycle 1 , Day 1 , 2 , 5 , 6 , 7 , 8 , 9 , 10 , 15 .</brief_summary>
	<brief_title>Plinabulin vs. Pegfilgrastim Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy</brief_title>
	<detailed_description>This multicenter , double-blind , randomize study phase 2 portion phase 3 portion . Approximately 190 patient enrol study . All patient receive docetaxel dose 75 mg/m2 . In Phase 2 , patient advance metastatic NSCLC fail platinum base therapy enrol . In Phase 3 , patient one follow enrol : advanced metastatic breast cancer , fail ≥ 1 &lt; 5 prior line chemotherapy ; advanced metastatic NSCLC fail platinum base therapy ; hormone refractory ( androgen independent ) metastatic prostate cancer . The eligibility patient determine 28-day screening period . Phase 2 : Approximately 40 patient advanced metastatic NSCLC enrol . Patients randomly assign , 10 patient enrolled arm , arm designation plan intervention follow : Arm 1 : Docetaxel ( 75 mg/m2 ) + pegfilgrastim ( 6 mg ) + placebo match plinabulin Arm 2 : Docetaxel ( 75 mg/m2 ) + plinabulin ( 20 mg/m2 ) + placebo match pegfilgrastim Arm 3 : Docetaxel ( 75 mg/m2 ) + plinabulin ( 10 mg/m2 ) + placebo match pegfilgrastim Arm 4 : Docetaxel ( 75 mg/m2 ) + plinabulin ( 5 mg/m2 ) + placebo match pegfilgrastim The study temporarily close enrollment 40 patient enrol complete least 1 treatment cycle arm phase 2 . The Sponsor notify study sit occurs . Once study temporarily close enrollment phase 2 , PK/PD analysis perform determine RP3D . The PK/PD analysis do independent party time 40 patient Phase 2 complete least Cycle 1 . This analysis blind study team . Phase 3 : Phase 3 begin RP3D determine base phase 2 PK/PD analysis mention ; RP3D plinabulin dose administer Phase 3 . Approximately 150 patient plan enrolled Phase 3 one follow diagnosis : advanced metastatic breast cancer , fail ≥ 1 &lt; 5 prior line chemotherapy ; advanced metastatic NSCLC fail platinum base therapy ; hormone refractory ( androgen independent ) metastatic prostate cancer . Each eligible patient stratify accord diagnosis ( advanced metastatic breast cancer , NSCLC , HRPC ) . Patients randomly assign equal probability ( 1:1 ratio ) 75:75 , arm designation plan intervention follow : Arm 1 : Docetaxel ( 75 mg/m2 ) + pegfilgrastim ( 6 mg ) + placebo match plinabulin Arm 2 : Docetaxel ( 75 mg/m2 ) + plinabulin ( RP3D ) + placebo match pegfilgrastim Data patient receive RP3D plinabulin dose Phase 2 Phase 3 pool assess primary secondary study endpoint , analyze separately .</detailed_description>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Diketopiperazines</mesh_term>
	<criteria>1 . At least ≥ 18 year age ( male female ) time sign informed consent form . 2 . ECOG performance status 0 1 . 3 . Patients : Phase 2 : Advanced metastatic NSCLC fail platinum base therapy Phase 3 : Advanced metastatic breast cancer , fail &lt; /= 1 &lt; 5 prior line chemotherapy Advanced metastatic NSCLC fail platinum base therapy Hormone refractory ( androgen independent ) metastatic prostate cancer ( HRPC ) . 4 . Pathology confirmation cancer require . 5 . Patients ≥ 1 follow risk factor , initiation docetaxel chemotherapy , would require neutropenia prophylaxis per National Comprehensive Cancer Network ( NCCN ) guideline ( version 2 , 2016 ) Myeloid Growth Factors ( refer Appendix C ) : Prior chemotherapy radiation treatment Bone marrow involvement tumor Surgery and/or open wound within 4 week first administration study drug Age &gt; 65 year age receive full chemotherapy dose intensity 6 . Life expectancy 3 month . 7 . The following laboratory result provide central laboratory within 14 day prior study drug administration : Hemoglobin &gt; /= 9 g/dL independent transfusion growth factor support Absolute neutrophil count &gt; /= 1.5 x 10**9/L independent growth factor support Serum total bilirubin &lt; /= 1.5 time upper limit normal ( ULN ) , unless patient diagnosis Gilbert 's disease case direct bilirubin &lt; 1.5 time ULN direct bilirubin . Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; /= 2.5 x ULN ( &lt; /= 1.5 x ULN alkaline phosphatase &gt; 2.5 x ULN ) Serum creatinine &lt; /= 1.5 x ULN 8 . Prothrombin time ( PT ) /International Normalized Ratio ( INR ) ≤ 1.5 × upper limit normal ( ULN ) , activate partial thromboplastin time ( PTT ) ≤ 1.5 × ULN , base central laboratory result . 9 . Female subject childbearing potential negative pregnancy test screening . Females childbearing potential define sexually mature woman without prior hysterectomy evidence menses past 12 month . However , woman amenorrhoeic 12 month still consider childbearing potential amenorrhea possibly due prior chemotherapy , antiestrogens , ovarian suppression . Women childbearing potential ( i.e. , menstruate woman ) must negative urine pregnancy test ( positive urine test confirm serum test ) document within 24hour period prior first dose study drug . Sexually active woman childbearing potential enrol study must agree use two form accept method contraception course study 3 month last dose study drug . Effective birth control include ( ) intrauterine device ( IUD ) plus one barrier method ; ( b ) stable dos hormonal contraception least 3 month ( e.g. , oral , injectable , implant , transdermal ) plus one barrier method ; ( c ) 2 barrier method . Effective barrier method male female condom , diaphragm , spermicide ( creams gel contain chemical kill sperm ) ; ( ) vasectomize partner . For male patient sexually active partner premenopausal woman : agreement use two form contraception treatment period least 3 month last dose study drug . 1 . History myelogenous leukemia , myelodysplastic syndrome concomitant sickle cell disease . 2 . Received chemotherapy within 4 week prior first dose study drug . 3 . Received prior docetaxel treatment , except docetaxel receive adjuvant therapy breast cancer &gt; 1 year first dose study drug . 4 . Received prior chemotherapy &gt; /= 5 line cytotoxic chemotherapy advance metastatic breast cancer ( adjuvant chemotherapy count one line chemotherapy , hormonal biological , non conjugate therapy [ e.g. , trastuzumab ] count line therapy ) . 5 . Current use strong cytochrome P450 ( CYP ) 3A4 inhibitor , within 3 day first administration study drug , 7 day treatment taxanes OR require use strong CYP3A4 inhibitor ( refer Section 11.6.2 ) 6 . Received investigational agent tumor vaccine within 2 week first dose study drug ; patient must recover toxicity prior treatment &gt; Grade 1 treatment emergent AEs . 7 . Receiving concurrent anticancer therapy . 8 . Received prior bone marrow stem cell transplant . 9 . Has coexist active infection receive systemic antiinfective treatment within 72 hour first dose study drug . 10 . Prior radiation therapy within 4 week first dose study drug . 11 . Prior use pegfilgrastim filgrastim within 4 week first dose study drug . 12 . Presence serious uncontrolled illness include , limited : uncontrolled diabetes , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , uncontrolled cardiac arrhythmia , uncontrolled arterial thrombosis , symptomatic pulmonary embolism , psychiatric illness would limit compliance study requirement , condition would preclude patient study treatment per discretion Investigator . 13 . Significant cardiovascular history : History myocardial infarction ischemic heart disease within 1 year first study drug administration ; Uncontrolled arrhythmia ; History congenital QT prolongation ; Electrocardiogram ( ECG ) finding consistent active ischemic heart disease ; New York Heart Association Class III IV cardiac disease ; Uncontrolled hypertension : blood pressure consistently &gt; 150 mm Hg systolic &gt; 100 mm Hg diastolic spite antihypertensive medication . 14 . History hemorrhagic diarrhea , inflammatory bowel disease , active uncontrolled peptic ulcer disease . ( Concomitant therapy ranitidine equivalent and/or omeprazole equivalent acceptable ) . History ileus significant gastrointestinal disorder know predispose ileus chronic bowel hypomotility . 15 . Any malignancy require active therapy . 16 . Known human immunodeficiency virus ( HIV ) seropositivity . 17 . Hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) infection require treatment . 18 . Female subject pregnant lactating . 19 . Unwilling unable comply procedure require protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Plinabulin</keyword>
	<keyword>Pegfilgrastim</keyword>
	<keyword>Duration Severe Neutropenia</keyword>
	<keyword>Bone Pain</keyword>
</DOC>